HIF-α prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review

K Hirota - Biomedicines, 2021 - mdpi.com
Oxygen is essential for the maintenance of the body. Living organisms have evolved
systems to secure an oxygen environment to be proper. Hypoxia-inducible factor (HIF) plays …

The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic …

K Takkavatakarn, T Thammathiwat… - Clinical Kidney …, 2023 - academic.oup.com
Renal anemia in chronic kidney disease (CKD) is associated with poor outcomes. Hypoxia-
inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and …

[HTML][HTML] Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial

YP Hou, XY Mao, C Wang, ZH Xu, ZH Bu, M Xu… - Journal of the Formosan …, 2022 - Elsevier
Background/purpose Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase
inhibitor, promotes erythropoiesis and regulates iron metabolism. This study investigated the …

[HTML][HTML] Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts

P Valent, G Büsche, I Theurl, IZ Uras, U Germing… - …, 2018 - ncbi.nlm.nih.gov
Pathological erythropoiesis with consequent anemia is a leading cause of symptomatic
morbidity in internal medicine. The etiologies of anemia are complex and include reactive as …

[HTML][HTML] Fatigue in individuals with end stage renal disease

CH Davey, AR Webel, AR Sehgal… - … journal: journal of the …, 2019 - ncbi.nlm.nih.gov
Fatigue is a subjective overwhelming feeling of tiredness at rest, exhaustion with activity,
lack of energy that impedes daily tasks, lack of endurance, or a loss of vigor. Individuals with …

An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease

Y Kurata, T Tanaka, M Nangaku - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Anemia is one of the major complications of chronic kidney disease (CKD).
Erythropoiesis-stimulating agents (ESAs) have been the mainstay of renal anemia treatment …

Additive effect of sarcopenia and anemia on the 10‐year risk of cardiovascular disease in patients with type 2 diabetes

F Zeng, L Huang, Y Zhang, X Hong… - Journal of Diabetes …, 2022 - Wiley Online Library
Objective. To investigate the association between sarcopenia and anemia and the 10‐year
cardiovascular disease risk in diabetic patients. Methods. A cross‐sectional study was …

Current status of renal anemia pharmacotherapy—what can we offer today

B Borawski, JS Malyszko, M Kwiatkowska… - Journal of Clinical …, 2021 - mdpi.com
Chronic kidney disease (CKD) is one of the fastest-growing major causes of death
internationally. Better treatment of CKD and its complications is crucial to reverse this …

Severity of anaemia and association with all-cause mortality in patients with medically managed left-sided endocarditis

MM Pries-Heje, RB Hasselbalch, C Wiingaard… - Heart, 2022 - heart.bmj.com
Objective To assess the prevalence and severity of anaemia in patients with left-sided
infective endocarditis (IE) and association with mortality. Methods In the Partial Oral versus …

New insights into molecular mechanisms of epigenetic regulation in kidney disease

I Mimura, T Tanaka, M Nangaku - Clinical and Experimental …, 2016 - Wiley Online Library
The number of patients with kidney failure has increased in recent years. Different factors
contribute to the progression of chronic kidney disease, including glomerular sclerosis …